Cagrilintide 10mg
LatestLOT CAG0002
99.84%HPLC purity · meets spec
- Labeled
- 10mg
- Measured
- 10.61mg
- Identity
- Confirmed
- Heavy metals
- Not Detected
- Sterility
- No Growth
- Endotoxin
- 0.103 EU/mL
- Tested
- Jul 30, 2026
8 assays passed · ISO/IEC 17025 accredited
Metabolic Peptide
Cagrilintide
NN9838CAS: 1415456-99-3ZP8396
A 37-amino acid long-acting acylated amylin analog that activates amylin and calcitonin receptors to modulate appetite signaling in homeostatic and hedonic brain regions, studied in clinical trials for weight management. Premium Direct-Supply Peptide.
MassChoose an option
Quantity
From$132
Fast, protected deliveryTracked USA shipping with discreet packaging.
Tracked USA delivery
Free shipment protection
Priority shipping available
Verified Test Results
Every batch, independently verified.
Each batch is analyzed by an ISO/IEC 17025 accredited third-party laboratory. The report below reflects the identity, purity and full-panel specification data reported by the lab.
ILSILS LaboratoriesCertificate of Analysis≥99%Purity by HPLC
ISO 17025 Accredited8× Tested
ParameterResultMethodSpecification
Peptide Purity (HPLC)99.84%HPLC>= 95%
Net Peptide Content10.61mgHPLCReport
Identity (HPLC)ConfirmedHPLCMeets spec
AppearanceGoodVisualMeets spec
Fentanyl ScreenNot DetectedImmunoassayPass
Heavy Metals (ICP-MS)Not DetectedICP-MSPass
Sterility (PCR)No GrowthPCRPass
Endotoxin (USP <85>)0.103 EU/mLUSP <85>Reported
Third-Party Verified
Certificate of Analysis
Every lot is HPLC-tested at an ISO/IEC 17025-accredited lab. Open any batch's certificate below.
Frequently Paired Products
Products commonly selected alongside this item
Compound Information
Technical specifications
MOLECULAR PROFILE
What Is Cagrilintide?
- Type
- Long-acting acylated amylin analog
- Amino acids
- 37 (modified amylin sequence)
- Molecular weight
- 4,409 g/mol
- CAS Number
- 1415456-99-3
- Molecular formula
- C₁₉₄H₃₁₂N₅₄O₅₉S₂
- Modification
- C18 fatty diacid acylation
STORAGE REQUIREMENTS
Stability Information
Store frozen or refrigeratedAvoid repeated freeze-thawProtect from light
Lyophilized (powder)Store at -20°C long-term
Reconstituted2-8°C
Light protectionProtect from light
Product Guides & References
Verified publications and source documentation
NEW ENGLAND JOURNAL OF MEDICINE
Coadministered Cagrilintide and Semaglutide in Adults with Overweight or Obesity
2025•DOI: 10.1056/NEJMoa2502081Garvey WT, Blüher M, Osorto Contreras CK et al.
View Source THE LANCETOnce-weekly cagrilintide for weight management in people with overweight and obesity: a multicentre, randomised, double-blind, placebo-controlled and active-controlled, dose-finding phase 2 trial
2021•PMID: 34798060Lau DCW et al.
View Source THE LANCETSafety, tolerability, pharmacokinetics, and pharmacodynamics of concomitant administration of multiple doses of cagrilintide with semaglutide 2.4 mg for weight management: a randomised, controlled, phase 1b trial
2021•PMID: 33894838Enebo LB et al.
View Source NATURE COMMUNICATIONSStructural and dynamic features of cagrilintide binding to calcitonin-family receptors
2025
View Source JOURNAL OF MEDICINAL CHEMISTRYDevelopment of Cagrilintide, a Long-Acting Amylin Analogue
2021
View Source CARDIOLOGY IN REVIEWCagrilintide: A Long-Acting Amylin Analog for the Treatment of Obesity
2024•DOI: 10.1097/CRD.0000000000000513•PMID: 36883831D'Ascanio AM, Mullally JA, Frishman WH
View Source PMCCagrilintide lowers bodyweight through brain amylin receptors 1 and 3
2025
View Source PUBCHEMCagrilintide — CID 171397054
View Source NOVO NORDISK (PRESS RELEASE)CagriSema demonstrated superior HbA1c reduction of 1.91%-points and weight loss of 14.2% in adults with type 2 diabetes in the REIMAGINE 2 trial
2026
View Source CLINICALTRIALS.GOV
